831 related articles for article (PubMed ID: 28762114)
1. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
[TBL] [Abstract][Full Text] [Related]
2. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?
Pilewskie M; Mautner SK; Stempel M; Eaton A; Morrow M
Ann Surg Oncol; 2016 Apr; 23(4):1123-8. PubMed ID: 26553439
[TBL] [Abstract][Full Text] [Related]
3. The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer.
Park TS; Thomas SM; Rosenberger LH; Fayanju OM; Plichta JK; Blitzblau RC; Ong CT; Hyslop T; Hwang ES; Greenup RA
Ann Surg Oncol; 2018 Oct; 25(10):3019-3029. PubMed ID: 29978365
[TBL] [Abstract][Full Text] [Related]
4. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Boughey JC
Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
8. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
[TBL] [Abstract][Full Text] [Related]
10. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
[TBL] [Abstract][Full Text] [Related]
11. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
[TBL] [Abstract][Full Text] [Related]
12. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
[TBL] [Abstract][Full Text] [Related]
13. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
14. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
[TBL] [Abstract][Full Text] [Related]
15. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.
Kantor O; Sipsy LM; Yao K; James TA
Ann Surg Oncol; 2018 May; 25(5):1304-1311. PubMed ID: 29368152
[TBL] [Abstract][Full Text] [Related]
16. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
[TBL] [Abstract][Full Text] [Related]
17. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
[TBL] [Abstract][Full Text] [Related]
18. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
[TBL] [Abstract][Full Text] [Related]
19. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
20. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.
Mamtani A; Zabor EC; Stempel M; Morrow M
Ann Surg Oncol; 2019 Oct; 26(10):3269-3274. PubMed ID: 31342363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
